Most cannabis driving research uses products far weaker than what people actually buy, creating a major evidence gap
Almost all cannabis driving research has used ~6% THC products, while today's market sells flower exceeding 20% THC and concentrates above 60%, creating a large gap between research and reality.
Quick Facts
What This Study Found
Nearly all driving impairment studies used inhaled cannabis at approximately 6% THC, far below the 20%+ THC flower and 60%+ THC concentrates now sold commercially. The dose-response relationship at higher potencies and the impairment timeline for different administration routes (edibles, vaping) remain largely unstudied.
Key Numbers
Research typically uses ~6% THC; commercial flower can exceed 20% THC; extracts can contain 60%+ THC; crash risk increases approximately 2-fold after smoking marijuana
How They Did This
Systematic review following PRISMA guidelines of PubMed literature and grey literature (congressional reports, committee reports, roadside surveys) on cannabis impairment and driving performance modeling.
Why This Research Matters
If driving research only tests products a fraction of the potency people actually use, the real-world impairment from modern cannabis products may be significantly underestimated, leaving a dangerous gap in safety knowledge.
The Bigger Picture
The mismatch between research cannabis and commercial cannabis undermines the evidence base for both driving laws and public safety messaging about cannabis impairment.
What This Study Doesn't Tell Us
Federal restrictions on cannabis research have limited access to products matching commercial potency. Many studies use vaporized rather than smoked cannabis. Naturalistic driving studies introduce uncontrollable variables.
Questions This Raises
- ?Does higher potency cannabis produce proportionally more driving impairment?
- ?How does the extended impairment timeline from edibles compare to inhalation?
- ?Can existing impairment models be recalibrated for modern-potency products?
Trust & Context
- Key Stat:
- Research uses ~6% THC while commercial products exceed 20-60% THC
- Evidence Grade:
- Systematic review identifying critical gaps between research conditions and real-world cannabis products
- Study Age:
- Published in 2021. Cannabis potency continues to increase in commercial markets.
- Original Title:
- Mechanisms of cannabis impairment: Implications for modeling driving performance.
- Published In:
- Forensic science international, 328, 110902 (2021)
- Authors:
- Burt, Thomas S(3), Brown, Timothy L(6), Milavetz, Gary(11), McGehee, Daniel V
- Database ID:
- RTHC-03035
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
How does cannabis affect driving?
Research shows crash risk approximately doubles after smoking cannabis. However, almost all studies used products around 6% THC, far weaker than the 20%+ THC products people actually buy.
Why is there a gap between cannabis research and reality?
Federal restrictions have limited researchers to low-potency cannabis. Commercial products now contain 3-10 times more THC than research products, meaning real-world impairment may be significantly greater than studies suggest.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-03035APA
Burt, Thomas S; Brown, Timothy L; Milavetz, Gary; McGehee, Daniel V. (2021). Mechanisms of cannabis impairment: Implications for modeling driving performance.. Forensic science international, 328, 110902. https://doi.org/10.1016/j.forsciint.2021.110902
MLA
Burt, Thomas S, et al. "Mechanisms of cannabis impairment: Implications for modeling driving performance.." Forensic science international, 2021. https://doi.org/10.1016/j.forsciint.2021.110902
RethinkTHC
RethinkTHC Research Database. "Mechanisms of cannabis impairment: Implications for modeling..." RTHC-03035. Retrieved from https://rethinkthc.com/research/burt-2021-mechanisms-of-cannabis-impairment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.